Immunoregulation by targeting T cells in the treatment of allergy and asthma

Current Opinion in Immunology

Volumn 18, Issue 6, 2006, Pages 745-750

  Larché, Mark ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; GRASS POLLEN EXTRACT; IMMUNOGLOBULIN E; IMMUNOLOGICAL ADJUVANT; IMMUNOSTIMULATING AGENT; INTERLEUKIN 10; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; PHOSPHOLIPASE A2; PHOSPHORYL LIPID A; POLLEN ANTIGEN; SYNTHETIC PEPTIDE; TRANSFORMING GROWTH FACTOR BETA; VACCINE;

ACCESSORY CELL; ALLERGIC ASTHMA; ALLERGIC DISEASE; BASOPHIL; CELL FUNCTION; CELL MATURATION; CELL SURVIVAL; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOKINE PRODUCTION; EFFECTOR CELL; EOSINOPHIL; HUMAN; IMMUNOGLOBULIN PRODUCTION; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOSTIMULATION; MAST CELL; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; TARGET CELL; TH1 CELL; TH2 CELL; UNSPECIFIED SIDE EFFECT;

ALLERGENS; ANIMALS; ASTHMA; DESENSITIZATION, IMMUNOLOGIC; HUMANS; HYPERSENSITIVITY; T-LYMPHOCYTES;

EID: 33750365602     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2006.09.013     Document Type: Review

References (37)

1. Haselden B.M., Kay A.B., and Larche M. Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions. J Exp Med 189 (1999) 1885-1894
2. Akdis M., Verhagen J., Taylor A., Karamloo F., Karagiannidis C., Crameri R., Thunberg S., Deniz G., Valenta R., Fiebig H., et al. Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med 199 (2004) 1567-1575
3. + regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease. Lancet 363 (2004) 608-615
4. Varney V.A., Hamid Q.A., Gaga M., Ying S., Jacobson M., Frew A.J., Kay A.B., and Durham S.R. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest 92 (1993) 644-651
5. + T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol 97 (1996) 1356-1365
6. + cells accompany inhibition of allergen-induced late skin responses after successful grass pollen immunotherapy. J Allergy Clin Immunol 99 (1997) 254-260
7. Jutel M., Pichler W.J., Skrbic D., Urwyler A., Dahinden C., and Muller U.R. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures. J Immunol 154 (1995) 4187-4194
8. + T cells from allergic individuals. J Exp Med 178 (1993) 2123-2130
9. Bellinghausen I., Metz G., Enk A.H., Christmann S., Knop J., and Saloga J. Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects. Eur J Immunol 27 (1997) 1131-1139
10. Akdis C.A., Akdis M., Blesken T., Wymann D., Alkan S.S., Muller U., and Blaser K. Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. J Clin Invest 98 (1996) 1676-1683
11. + T cells by grass pollen immunotherapy. J Allergy Clin Immunol 111 (2003) 1255-1261
12. Nouri-Aria K.T., Wachholz P.A., Francis J.N., Jacobson M.R., Walker S.M., Wilcock L.K., Staple S.Q., Aalberse R.C., Till S.J., and Durham S.R. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol 172 (2004) 3252-3259
13. Nasser S.M., Ying S., Meng Q., Kay A.B., and Ewan P.W. Interleukin-10 levels increase in cutaneous biopsies of patients undergoing wasp venom immunotherapy. Eur J Immunol 31 (2001) 3704-3713
14. Akdis C.A., and Blaser K. IL-10-induced anergy in peripheral T cell and reactivation by microenvironmental cytokines: two key steps in specific immunotherapy. FASEB J 13 (1999) 603-609
15. Jutel M., Akdis M., Budak F., Aebischer-Casaulta C., Wrzyszcz M., Blaser K., and Akdis C.A. IL-10 and TGF-β cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 33 (2003) 1205-1214
16. Tarzi M., Klunker S., Texier C., Verhoef A., Stapel S.O., Akdis C.A., Maillere B., Kay A.B., and Larche M. Induction of interleukin-10 and suppressor of cytokine signaling-3 gene expression following peptide immunotherapy. Clin Exp Allergy 36 (2006) 465-474
17. Akdis C.A., Blesken T., Akdis M., Wuthrich B., and Blaser K. Role of interleukin 10 in specific immunotherapy. J Clin Invest 102 (1998) 98-106
18. Jutel M., Jaeger L., Suck R., Meyer H., Fiebig H., and Cromwell O. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol 116 (2005) 608-613. This was the first study to use purified recombinant native allergens for immunotherapy. The use of a limited number of proteins was at least as efficacious as standard SIT using allergen extract preparations, suggesting that carefully selected panels of major allergens can substitute for natural extracts. Furthermore, the low levels of endotoxin in the recombinant preparation means that endotoxin was not partially responsible for the clinical effect, as had been suggested in previous studies with allergen extracts.
19. Bolhaar S.T., Zuidmeer L., Ma Y., Ferreira F., Bruijnzeel-Koomen C.A., Hoffmann-Sommergruber K., van Ree R., and Knulst A.C. A mutant of the major apple allergen, Mal d 1, demonstrating hypo-allergenicity in the target organ by double-blind placebo-controlled food challenge. Clin Exp Allergy 35 (2005) 1638-1644. This is the first study to use a recombinant hypoallergenic allergen preparation for food provocation challenge. This small study suggests that biological assays, rather than simple measurements of IgE binding, might be more accurate for assessing allergenicity relative to the native protein. Double-blind, placebo-controlled food challenge confirmed reduced allergenicity of the preparation in a small group of subjects.
20. van Hage-Hamsten M., Kronqvist M., Zetterstrom O., Johansson E., Niederberger V., Vrtala S., Gronlund H., Gronneberg R., and Valenta R. Skin test evaluation of genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1: results obtained with a mix of two recombinant Bet v 1 fragments and recombinant Bet v 1 trimer in a Swedish population before the birch pollen season. J Allergy Clin Immunol 104 (1999) 969-977
21. Niederberger V., Horak F., Vrtala S., Spitzauer S., Krauth M.T., Valent P., Reisinger J., Pelzmann M., Hayek B., and Kronqvist M. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci USA 101 Suppl 2 (2004) 14677-14682
22. 3 was not detected.
23. Gafvelin G., Thunberg S., Kronqvist M., Gronlund H., Gronneberg R., Troye-Blomberg M., Akdis M., Fiebig H., Purohit A., and Horak F. Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1. Int Arch Allergy Immunol 138 (2005) 59-66
24. Larche M., and Wraith D.C. Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat Med 11 (2005) S69-S76
25. Norman P.S., Ohman J.L., Long A.A., Creticos P.S., Gefter M.A., Shaked Z., Wood R.A., Eggleston P.A., Hafner K.B., Rao P., et al. Treatment of cat allergy with T-cell reactive peptides. Am J Respir Crit Care Med 154 (1996) 1623-1628
26. Oldfield W.L., Larche M., and Kay A.B. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet 360 (2002) 47-53
27. + T helper type 1 cells to sites of allergen-induced late-phase skin reactions in cat-allergic subjects. Clin Exp Allergy 35 (2005) 52-58
28. + T cell population with regulatory activity. PLoS Med 2 (2005) e78. Previous peptide immunotherapy studies reported suppressed T-cell proliferative responses and Th1/Th2 cytokine responses to allergen. Some studies reported increased IL-10 production. Mechanisms were not defined and might have included deletion of allergen-specific cells, the induction of anergy and the induction of regulatory T cells. This study provides the first evidence that functional Treg cells are induced by peptide intervention.
29. Muller U., Akdis C.A., Fricker M., Akdis M., Blesken T., Bettens F., and Blaser K. Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol 101 (1998) 747-754
30. Fellrath J.M., Kettner A., Dufour N., Frigerio C., Schneeberger D., Leimgruber A., Corradin G., and Spertini F. Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: results of a phase I trial. J Allergy Clin Immunol 111 (2003) 854-861
31. Simons F.E., Shikishima Y., Van Nest G., Eiden J.J., and HayGlass K.T. Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. J Allergy Clin Immunol 113 (2004) 1144-1151
32. Tulic M.K., Fiset P.O., Christodoulopoulos P., Vaillancourt P., Desrosiers M., Lavigne F., Eiden J., and Hamid Q. Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J Allergy Clin Immunol 113 (2004) 235-241
33. Drachenberg K.J., Wheeler A.W., Stuebner P., and Horak F. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 56 (2001) 498-505
34. Mothes N., Heinzkill M., Drachenberg K.J., Sperr W.R., Krauth M.T., Majlesi Y., Semper H., Valent P., Niederberger V., Kraft D., and Valenta R. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy 33 (2003) 1198-1208
35. Mamessier E., Birnbaum J., Dupuy P., Vervloet D., and Magnan A. Ultra-rush venom immunotherapy induces differential T cell activation and regulatory patterns according to the severity of allergy. Clin Exp Allergy 36 (2006) 704-713
36. + T helper type 2 cells. J Exp Med 183 (1996) 759-768
37. Seidel-Guyenot W., Perschon S., Dechant N., Alt R., Knop J., and Steinbrink K. Low zone tolerance induced by systemic application of allergens inhibits Tc1-mediated skin inflammation. J Allergy Clin Immunol 117 (2006) 1170-1177